Company intelligence / Profile preview
OnKure Therapeutics
Boulder, Colorado, United Statesonkuretherapeutics.com ↗
- Ownership
- Public · OKUR
- Development stage
- Phase 1
01
Overview
Preliminary safety, tolerability, and pharmacokinetic data from the first-in-human PIKture‑01 trial of OKI‑219 have been encouraging as of December 2024. The company has sufficient cash runway into Q4–2026 and continues to advance its lead candidate through early clinical development.[2]
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Investors include Acorn Bioventures, Cormorant Asset Management, Deep Track Capital, Perceptive Advisors, Samsara BioCapital, Surveyor Capital (Citadel), Vestal Point Capital.[5][7]
04
Financials
- Market cap
- $102.3M
- Total revenue
- $0
- Enterprise value
- $-60.3M
Beyond the preview
Go deeper on OnKure Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OnKure Therapeutics.